Mutations in cancer predisposition genes and risk for subsequent neoplasms

Final overall survival analysis of MONARCH 1

Redefining tamoxifen for breast cancer

Olaparib and temozolomide for relapsed small cell lung cancer

Treatment choices for HER2 amplified colorectal cancer

Final results of the HERACLES trial in HER2-amplified colorectal cancer

Results of SUMMIT: a global phII trial of neratinib in HER2/3 mutant solid tumours

Neratinib in HER2 or HER3 mutant solid tumours

Understanding response and resistance to cancer therapy: Lessons learned from melanoma

Tumour treating fields added to standard chemotherapy in newly diagnosed glioblastoma (GBM):

Tumour-treating fields complement chemotherapy in aggressive brain tumours

Caring for HIV positive transgender patients